A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Study of Ustekinumab, a Human Monoclonal Antibody to Il-12/23p40, in Patients with Moderately to Severely Active Crohnʼs Disease: Results through Week 36 from the CERTIFI Trial: 2011 ACG Presidential Poster

Feagan, Brian G.; Gasink, Christopher; Gao, Ling; Ma, Blank; Johanns, Jewel; Guzzo, Cynthia; Sands, B E; Hanauer, Stephen B.; Targan, Stephan; Rutgeerts, Paul; Ghosh, Subrata; Villiers, Willem de; Panaccione, Remo; Greenberg, G.R.; Schreiber, Stefanie; Lichtiger, Simon; Sandborn, William J.

doi:10.14309/00000434-201110002-01227

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

2019

Publication Types

Select...

Article2

Other1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

Khanna

Preiß

MacDonald

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Although we are uncertain about the efficacy of ustekinumab for induction of remission, moderate quality evidence suggests that ustekinumab may be effective for induction of clinical improvement in patients with moderate to severe CD. Due to small numbers of patients in dose subgroups the optimal dosage of ustekinumab is unclear. Briakinumab and ustekinumab appear to be safe. Due to sparse data we were unable to determine the risk of serious adverse events. Further studies are required to determine the efficacy and safety of ustekinumab in patients with moderate to severe CD. The results of three phase III trials that are currently underway will provide important new information.

show abstract

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

Khanna

Preiß

MacDonald

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

MacDonald

Nguyen

Khanna

et al. 2016

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

High quality evidence suggests that ustekinumab is effective for induction of clinical remission and clinical improvement in patients with moderate to severe Crohn's disease. Moderate to high quality evidence suggests that the optimal dosage of ustekinumab is 6 mg/kg. Briakinumab and ustekinumab appear to be safe. Moderate quality evidence suggests no increased risk of serious adverse events. Future studies are required to determine the long-term efficacy and safety of ustekinumab in patients with moderate to severe Crohn's disease.

show abstract